Cassandra will be joining the company as Managing Director, while also sitting on FreshLeaf Analytics' advisory board.
There was big news from FreshLeaf Analytics—which operates as a division of Southern Cannabis Holdings (SCH)—earlier today, after the organisation announced a key expansion to its management team, with the addition of strategy and innovation specialist Cassandra Hunt.
Cassandra will be taking on the role of Managing Director, where she will make use of her extensive experience with pharmaceutical, life sciences, healthcare, and consumer goods organisations.
We are extremely pleased to welcome someone as exceptional as Cass to the FreshLeaf team. Cass has a proven track record of performing at the highest levels of the consulting industry and is perfectly positioned to take our business through its next phase of growth. Southern Cannabis Holdings Director, Tim Drury
Prior to joining FreshLeaf Cassandra also served as a partner for the information technology firm, Accenture, and has worked as a growth and innovation advisor for companies around the world.
As part of her new role, Cassandra will also take up a seat on the FreshLeaf Analytics advisory board alongside the Director of SCH, Tim Drury, to help push the company towards its "next growth phase".
As part of the expansion FreshLeaf also announced that the company's Principal Consultant, Rhys Cohen, will be transitioning to a part time role with the company as a member of its advisory board.
"Rhys has been a leading voice in the industry since its outset and we have been fortunate to have him working with us on FreshLeaf consulting projects over the past year," SCH Director Tim Drury said.
"We look forward to our next phase of collaboration with Rhys as part of our advisory board."
Cohen has confirmed that he will continue to remain an active commentator on the cannabis industry and is only scaling back his involvement with the company so that he can pursue further studies.
The addition of Cassandra represents the latest in a series of attention-grabbing announcements from Southern Cannabis Holdings in 2020, which included the launch of groundbreaking studies into chronic pain and anxiety, as well as the decision to cut costs for 70% of CA Clinics patients.
"COVID-19 has created a lot of anxiety and financial uncertainty for many patients, so our clinics business has launched this new pricing initiative in order to better meet their needs," Drury said.
"Ultimately, paving a path to greater affordability and accessibility to medicinal cannabis as a treatment option is a shared goal of the industry, regulators and advocates alike."
FreshLeaf has also confirmed that it is on schedule to release the latest instalment of its widely-read Market Report—which analyses the Australian cannabis industry in microscopic detail—during Q3 2020.
This pot stock could reach new heights in 2020 due to Coronavirus
The COVID-19 pandemic is showing no signs of slowing down, and as global markets enter meltdown many cannabis companies are feeling the effects of capital crunch.
While the market crash will continue for some time, it represents a golden opportunity for investors who are capable of riding out the volatility until share prices rally.
Luckily, one pot stock has developed antimicrobial drug that can already treat two superbugs while limiting their ability to develop antibiotic resistance.
Investors can also start picking up shares at rock bottom prices, as global investor sentiment continues to dampen thanks to COVID-19.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors